SeekingAlpha · Sep 17, 2026
Summit Therapeutics: It's Okay Not To Have An Answer
Summit Therapeutics' ivonescimab data looks promising but uncertain amid dilution, royalties and catalysts. See why I rate SMMT stock a Hold right now.
NASDAQ · SMMT
Healthcare · Biotechnology
$17.85
Up+$0.13 (+0.73%)
Updated Sep 20, 2026, 5:06 PM
SID Score
5.7/10
Composite research score
Smart Money
61/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
SMMT closed at $17.85 after 19 trading sessions, up 40.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $17.735 | $17.87 | $17.31 | $17.85 | 13.06M |
| Sep 17, 2026 | $17.73 | $18.10 | $17.42 | $17.72 | 6.13M |
| Sep 16, 2026 | $17.50 | $17.75 | $17.11 | $17.30 | 6.09M |
| Sep 15, 2026 | $18.16 | $18.47 | $17.11 | $17.40 | 5.8M |
| Sep 14, 2026 | $18.07 | $18.83 | $17.97 | $18.42 | 7.07M |
| Sep 11, 2026 | $17.20 | $17.70 | $17.1375 | $17.55 | 4.28M |
| Sep 10, 2026 | $17.30 | $17.6208 | $16.80 | $17.00 | 4.22M |
| Sep 9, 2026 | $18.205 | $18.3216 | $17.24 | $17.54 | 4.8M |
| Sep 8, 2026 | $17.43 | $17.69 | $16.967 | $17.28 | 7.36M |
| Sep 4, 2026 | $16.935 | $17.63 | $16.80 | $17.605 | 6.95M |
| Sep 3, 2026 | $15.52 | $17.35 | $15.515 | $17.13 | 14.92M |
| Sep 2, 2026 | $14.15 | $14.72 | $14.06 | $14.60 | 3.78M |
| Sep 1, 2026 | $13.38 | $14.475 | $13.37 | $14.16 | 4.7M |
| Aug 31, 2026 | $13.51 | $13.73 | $13.44 | $13.62 | 5.43M |
| Aug 28, 2026 | $14.11 | $14.24 | $13.43 | $13.73 | 3.91M |
| Aug 27, 2026 | $14.30 | $14.65 | $13.92 | $14.33 | 4.84M |
| Aug 26, 2026 | $14.75 | $15.10 | $14.1137 | $14.23 | 11.63M |
| Aug 25, 2026 | $13.27 | $13.60 | $13.05 | $13.36 | 6.33M |
| Aug 24, 2026 | $13.08 | $13.21 | $12.22 | $12.73 | 4.39M |
The latest Smart Investors Daily articles mentioning SMMT.


SMMT research
Filterable reporting and market headlines.
Filters are reflected in the page URL for sharing and back-button support.
5 matching articles.
SeekingAlpha · Sep 17, 2026
Summit Therapeutics' ivonescimab data looks promising but uncertain amid dilution, royalties and catalysts. See why I rate SMMT stock a Hold right now.
Yahoo · Sep 16, 2026
Summit Therapeutics (SMMT) is back in focus after presenting new Phase III ivonescimab data in non small cell lung cancer, including updated overall survival and safety results, at the IASLC 2026 World Conference on Lung Cancer. Those fresh ivonescimab updates land after a sharp run, with Summit Therapeutics’ 30 day share price return of 30.34% and 90 day gain of 23.67% contrasting with a slightly negative year to date move. At the same time, the 3 year total shareholder return above 8x hints...
Benzinga · Sep 15, 2026
Updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the
Yahoo · Sep 15, 2026
MIAMI, September 15, 2026--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea.
Yahoo · Sep 14, 2026
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
The latest Smart Investors Daily articles mentioning SMMT.